ATE511400T1 - Nukleinsäure-fomulierungen zur genverabreichung - Google Patents

Nukleinsäure-fomulierungen zur genverabreichung

Info

Publication number
ATE511400T1
ATE511400T1 AT01918339T AT01918339T ATE511400T1 AT E511400 T1 ATE511400 T1 AT E511400T1 AT 01918339 T AT01918339 T AT 01918339T AT 01918339 T AT01918339 T AT 01918339T AT E511400 T1 ATE511400 T1 AT E511400T1
Authority
AT
Austria
Prior art keywords
poly
acid
nucleic acid
acid formulations
gene administration
Prior art date
Application number
AT01918339T
Other languages
German (de)
English (en)
Inventor
Jason Fewell
Fiona Maclaughlin
Louis Smith
Francois Nicol
Alain Rolland
Original Assignee
Genetronics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetronics Inc filed Critical Genetronics Inc
Application granted granted Critical
Publication of ATE511400T1 publication Critical patent/ATE511400T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT01918339T 2000-03-03 2001-03-02 Nukleinsäure-fomulierungen zur genverabreichung ATE511400T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18723600P 2000-03-03 2000-03-03
US26175101P 2001-01-16 2001-01-16
PCT/US2001/006953 WO2001066149A2 (en) 2000-03-03 2001-03-02 Nucleic acid formulations for gene delivery and methods of use

Publications (1)

Publication Number Publication Date
ATE511400T1 true ATE511400T1 (de) 2011-06-15

Family

ID=26882847

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01918339T ATE511400T1 (de) 2000-03-03 2001-03-02 Nukleinsäure-fomulierungen zur genverabreichung

Country Status (9)

Country Link
US (2) US7173116B2 (cg-RX-API-DMAC7.html)
EP (1) EP1259265B1 (cg-RX-API-DMAC7.html)
JP (1) JP4987205B2 (cg-RX-API-DMAC7.html)
AT (1) ATE511400T1 (cg-RX-API-DMAC7.html)
AU (1) AU2001245427A1 (cg-RX-API-DMAC7.html)
BR (1) BR0108962A (cg-RX-API-DMAC7.html)
CA (1) CA2401327C (cg-RX-API-DMAC7.html)
DK (1) DK1259265T3 (cg-RX-API-DMAC7.html)
WO (1) WO2001066149A2 (cg-RX-API-DMAC7.html)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE309358T1 (de) * 1999-07-26 2005-11-15 Baylor College Medicine Superaktive, wachstumshormone freisetzende hormonanaloge vom schwein
US20040192593A1 (en) * 1999-07-26 2004-09-30 Baylor College Of Medicine Protease resistant ti-growth hormone releasing hormone
AU2001296354A1 (en) 2000-09-25 2002-04-02 Baylor College Of Medicine Improved system for regulation of transgene expression
CA2464199C (en) * 2001-10-26 2013-12-24 Baylor College Of Medicine A composition and method to alter lean body mass and bone properties in a subject
US20030191081A1 (en) * 2001-12-28 2003-10-09 Pierre Lemieux Pharmaceutical compositions and methods of use thereof comprising polyanionic polymers and amphiphilic block copolymers to improve gene expression
US20040014645A1 (en) * 2002-05-28 2004-01-22 Advisys, Inc. Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system
BR0311539A (pt) * 2002-05-28 2005-10-25 Advisys Inc Liberação aumentada de um constructo de ácido nucléico in vivo pelo sistema de poli-l-glutamato ("plg")
US20080269153A1 (en) * 2002-05-28 2008-10-30 Ruxandra Draghia-Akli Increased stability of a dna formulation by including poly-l-glutamate
TW200403338A (en) * 2002-07-16 2004-03-01 Advisys Inc Codon optimized synthetic plasmids
AU2003302337A1 (en) * 2002-12-31 2004-07-29 The Johns Hopkins University Wound healing method and kits
WO2004067719A2 (en) * 2003-01-28 2004-08-12 Advisys, Inc. Growth hormone releasing hormone (ghrh) for use in reducing culling in herd animals
US7824907B2 (en) * 2003-03-11 2010-11-02 Merck Serono Sa Expression vectors comprising the mCMV IE2 promoter
AU2004229465B2 (en) * 2003-04-09 2010-04-29 The United States Of America Department Of Veterans Affairs Compositions and methods related to production of erythropoietin
TW200424214A (en) * 2003-04-21 2004-11-16 Advisys Inc Plasmid mediated GHRH supplementation for renal failures
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
US20090005333A1 (en) * 2004-01-26 2009-01-01 Vgx Pharmaceuticlas, Inc. Reducing culling in herd animals growth hormone releasing hormone (ghrh)
EP1804839B1 (en) * 2004-09-22 2012-03-14 St. Jude Children's Research Hospital Improved expression of factor ix in gene therapy vectors
US20060094023A1 (en) * 2004-11-02 2006-05-04 Industrial Technology Research Institute Method for isolating nucleic acid by using amino surfactants
TWI294460B (en) * 2004-12-23 2008-03-11 Ind Tech Res Inst Method for stabilizing nucleic acids
CA2631719A1 (en) * 2005-12-07 2007-10-25 Genetronics, Inc. Variable volume electroporation chamber and methods therefore
WO2007103070A2 (en) 2006-03-03 2007-09-13 Genetronics, Inc. Method and device for treating microscopic residual tumors remaining in tissues following surgical resection
ES2434169T3 (es) 2006-11-08 2013-12-13 Veritas Bio, Llc Entrega in vivo de ARN bicatenario a una célula objetivo
FR2941152B1 (fr) * 2009-01-20 2013-10-18 Centre Nat Rech Scient Vecteurs comprenant une macromolecule anionique et un lipide cationique pour l'administration de petits acides nucleiques.
WO2012018594A2 (en) * 2010-07-26 2012-02-09 Scott & White Healthcare Plant-derived polysaccharides for delivery of rna-based therapies
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
CN104203287B (zh) 2011-07-12 2017-07-14 费城健康及教育公司，d/b/a,德雷克塞尔大学医学院 新型艰难梭菌dna疫苗
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US10421960B2 (en) 2011-09-16 2019-09-24 The Trustees Of The University Of Pennsylvania RNA engineered T cells for the treatment of cancer
WO2013044225A1 (en) 2011-09-22 2013-03-28 The Trustees Of The University Of Pennsylvania A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9272002B2 (en) 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
SMT202200355T1 (it) 2011-12-16 2022-11-18 Modernatx Inc Composizioni di mrna modificato
JP2015509716A (ja) 2012-02-22 2015-04-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 第二世代キメラ抗原受容体におけるｃｄ２シグナル伝達ドメインの使用
EP4230647A1 (en) 2012-02-22 2023-08-23 The Trustees of the University of Pennsylvania Use of icos-based cars to enhance antitumor activity and car persistence
EP2834260A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP2015524255A (ja) 2012-07-13 2015-08-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 二重特異性抗体を共導入することによってｃａｒｔ細胞の活性を強化する方法
AR092745A1 (es) 2012-10-01 2015-04-29 Univ Pennsylvania Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
US9677078B2 (en) 2012-10-08 2017-06-13 Lipocalyx Gmbh Carboxylated polyamine derivatives as transfection reagents
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
SI2956477T2 (sl) 2013-02-15 2024-05-31 Bioverativ Therapeutics Inc. Optimiran gen dejavnika VIII
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
EP4303229A3 (en) 2014-01-21 2024-04-17 Novartis AG Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
CN107206024B (zh) 2014-10-31 2021-12-03 宾夕法尼亚大学董事会 改变cart细胞中的基因表达及其用途
EP4653013A2 (en) 2014-10-31 2025-11-26 The Trustees of the University of Pennsylvania Methods and compositions for modified t cells
CN107106609A (zh) 2014-10-31 2017-08-29 宾夕法尼亚大学董事会 刺激和扩展t细胞的组合物和方法
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
ES2947589T3 (es) 2015-01-31 2023-08-11 Univ Pennsylvania Composiciones y métodos para el suministro de moléculas terapéuticas a linfocitos T
RU2754661C2 (ru) 2015-05-01 2021-09-06 Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния Гликанзависимые иммунотерапевтические молекулы
EP4218777A3 (en) 2015-08-28 2023-08-23 The Trustees of the University of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
PT3411478T (pt) 2016-02-01 2022-09-13 Bioverativ Therapeutics Inc Genes do fator viii otimizados
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
US10233419B2 (en) 2016-06-30 2019-03-19 Zymergen Inc. Apparatuses and methods for electroporation
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
AU2018246143B2 (en) 2017-03-28 2025-06-05 The Trustees Of The University Of Pennsylvania Methods to protect transplanted tissue from rejection
WO2019129851A1 (en) 2017-12-29 2019-07-04 Cellectis Method for improving production of car t cells
WO2019191114A1 (en) 2018-03-27 2019-10-03 The Trustees Of The University Of Pennsylvania Modified immune cells having enhanced function and methods for screening for same
US12343397B2 (en) 2018-05-17 2025-07-01 Regents Of The University Of Minnesota Drug-resistant immune cells and methods of use thereof
WO2020037142A1 (en) 2018-08-17 2020-02-20 Yale University Compositions and methods for high-throughput activation screening to boost t cell effector function
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US20220170097A1 (en) 2018-10-29 2022-06-02 The Broad Institute, Inc. Car t cell transcriptional atlas
US20220177863A1 (en) 2019-03-18 2022-06-09 The Broad Institute, Inc. Type vii crispr proteins and systems
CN113661180B (zh) 2019-03-27 2025-08-26 宾夕法尼亚大学董事会 Tn-MUC1嵌合抗原受体(CAR)T细胞疗法
JP2022549932A (ja) 2019-09-30 2022-11-29 バイオベラティブ セラピューティクス インコーポレイテッド レンチウイルスベクター製剤
WO2021108050A2 (en) 2019-10-23 2021-06-03 Yale University Compositions and methods comprising viral vector systems for multiplexed activation of endogenous genes as immunotherapy and viral-based immune-gene therapy
WO2021178896A1 (en) 2020-03-06 2021-09-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
JP2023519346A (ja) 2020-03-27 2023-05-10 メンドゥス・ベスローテン・フェンノートシャップ 養子細胞療法の有効性を増強するための白血病由来の改変細胞のエクスビボ（ｅｘ ｖｉｖｏ）使用
US20210322471A1 (en) 2020-03-27 2021-10-21 Dcprime B.V. In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
US12173307B2 (en) 2020-06-24 2024-12-24 Bioverativ Therapeutics Inc. Methods for the purification of viral vectors
CA3182607A1 (en) 2020-06-30 2022-01-06 Erik Hans MANTING Use of leukemia-derived cells in ovarian cancer vaccines
EP4210832A1 (en) 2020-09-14 2023-07-19 Vor Biopharma, Inc. Chimeric antigen receptors for treatment of cancer
WO2022097068A1 (en) 2020-11-05 2022-05-12 Dcprime B.V. Use of tumor-independent antigens in immunotherapies
EP4281102A1 (en) 2021-01-22 2023-11-29 Mendus B.V. Methods of tumor vaccination
WO2022187591A1 (en) 2021-03-05 2022-09-09 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
US20220305100A1 (en) 2021-03-12 2022-09-29 Dcprime B.V. Methods of vaccination and use of cd47 blockade
US20250101126A1 (en) 2021-08-05 2025-03-27 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
AU2022339667A1 (en) 2021-09-03 2024-04-11 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
WO2023034571A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
US20240002800A1 (en) 2022-05-16 2024-01-04 Mendus B.V. Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy
WO2024236547A1 (en) 2023-05-18 2024-11-21 Inceptor Bio, Llc Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof
WO2025046513A1 (en) 2023-08-29 2025-03-06 Inceptor Bio, Llc Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof
CN119925619A (zh) * 2024-12-31 2025-05-06 首都医科大学 一种递送外源质粒dna的赋形剂及其制备和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4543252A (en) * 1982-01-21 1985-09-24 The Regents Of The University Of California Cationic oligopeptides having microbicidal activity
EP0130935B1 (fr) 1983-07-01 1987-04-15 Battelle Memorial Institute Polypeptide biodégradable et son utilisation pour le relargage progressif de médicaments
DE3581471D1 (de) 1984-10-19 1991-02-28 Battelle Memorial Institute Durch mikroorganismen abbaubares polypeptid und seine verwendung fuer die fortschreitende abgabe von medikamenten.
US5749847A (en) * 1988-01-21 1998-05-12 Massachusetts Institute Of Technology Delivery of nucleotides into organisms by electroporation
JP3368603B2 (ja) 1992-02-28 2003-01-20 オリンパス光学工業株式会社 遺伝子治療用処置具
US5439440A (en) 1993-04-01 1995-08-08 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
AU6714094A (en) 1993-04-28 1994-11-21 Ribozyme Pharmaceuticals, Inc. Ocular delivery of nucleic acid
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
WO1995024929A2 (en) 1994-03-15 1995-09-21 Brown University Research Foundation Polymeric gene delivery system
US6271205B1 (en) * 1994-09-21 2001-08-07 University Of Massachusetts Medical Center Cancer treatment by expression of differentiation factor receptor
US6040295A (en) * 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
FR2732218B1 (fr) 1995-03-28 1997-08-01 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s) et leurs procedes de preparation
GB9600272D0 (en) * 1996-01-06 1996-03-06 Univ Nottingham Polymers
US5704908A (en) 1996-10-10 1998-01-06 Genetronics, Inc. Electroporation and iontophoresis catheter with porous balloon
GB9623051D0 (en) 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
US6048551A (en) 1997-03-27 2000-04-11 Hilfinger; John M. Microsphere encapsulation of gene transfer vectors
FR2766706B1 (fr) 1997-07-30 2001-05-25 Biovector Therapeutics Sa Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation
US6040925A (en) 1997-12-12 2000-03-21 Hewlett-Packard Company Radial and pruned radial interpolation
US6383811B2 (en) 1997-12-30 2002-05-07 Mirus Corporation Polyampholytes for delivering polyions to a cell
EP2428250A1 (en) * 1998-07-13 2012-03-14 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US7396919B1 (en) * 1998-07-17 2008-07-08 Mirus Bio Corporation Charge reversal of polyion complexes
US5945290A (en) * 1998-09-18 1999-08-31 Isis Pharmaceuticals, Inc. Antisense modulation of RhoA expression
FR2786098B1 (fr) * 1998-11-20 2003-05-30 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
WO2000078791A2 (en) 1999-06-17 2000-12-28 Universiteit Gent FUNCTIONAL POLY-α-AMINOACID DERIVATIVES USEFUL FOR THE MODIFICATION OF BIOLOGICALLY ACTIVE MATERIALS AND THEIR APPLICATION
WO2000078358A2 (en) 1999-06-18 2000-12-28 The Collaborative Group, Ltd. Hyaluronic acid microspheres for sustained gene transfer
WO2001013723A1 (en) 1999-08-20 2001-03-01 Mirus Corporation Charge reversal of polyion complexes
JP2003525613A (ja) * 2000-03-03 2003-09-02 バレンティス，インコーポレイティド 核酸送達用の改良ポロキサマーおよびポロキサミン組成物
AU2001296354A1 (en) * 2000-09-25 2002-04-02 Baylor College Of Medicine Improved system for regulation of transgene expression

Also Published As

Publication number Publication date
US7173116B2 (en) 2007-02-06
US20070213287A1 (en) 2007-09-13
JP4987205B2 (ja) 2012-07-25
US20030109478A1 (en) 2003-06-12
BR0108962A (pt) 2002-12-24
EP1259265A2 (en) 2002-11-27
WO2001066149A2 (en) 2001-09-13
CA2401327A1 (en) 2001-09-13
JP2003525912A (ja) 2003-09-02
US7491537B2 (en) 2009-02-17
DK1259265T3 (da) 2011-07-11
WO2001066149A3 (en) 2002-03-14
EP1259265B1 (en) 2011-06-01
AU2001245427A1 (en) 2001-09-17
CA2401327C (en) 2014-05-06

Similar Documents

Publication Publication Date Title
ATE511400T1 (de) Nukleinsäure-fomulierungen zur genverabreichung
MXPA03011784A (es) Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
ZA200206723B (en) Cosmetic compositions containing a methacrylic acid copolymer, a silicone and a cationic polymer, and uses thereof.
DE60142616D1 (de) Hydrogelzusammensetzung zur transdermalen arzneistoffabgabe
AU2002301098A1 (en) Cosmetic compositions containing a methacrylic acid copolymer, a silicone and a cationic polymer, and uses thereof
ATE244556T1 (de) Biologisch abbaubare ph/thermosensitive hydrogele zur verzörgerten freisetzung biologisch aktiver stoffe
FR2829387B1 (fr) Compositions cosmetiques contenant un copolymere d'acide methacrylique, une dimethicone et un polymere cationique et leurs utilisations
AU2002300821A1 (en) Cosmetic compositions containing a methacrylic acid copolymer, a silicone and a cationic polymer, and uses thereof
DE69943084D1 (de) Mucoadhäsive zusammensetzung zur verabreichung von biologisch aktiven substanzen in tiergewebe
GB0317999D0 (en) Improvements in or relating to drug delivery systems
MY130332A (en) Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer
DE69940635D1 (de) Copolymer-zusammensetzungen zur oralen verabreichung
MXPA03004828A (es) Composiciones de poliomeros de dispersion liquida, su preparacion y su uso.
FR2819179B1 (fr) Compositions photoprotectrices a base de polymeres amphiphiles
AU2357202A (en) Ion-strength independent sustained release pharmaceutical formulation
BR0108056A (pt) Preparados cosméticos com extratos waltheria indica
ATE314084T1 (de) Kahalalid f formulierung
ZA200206724B (en) Cosmetic compositions containing a methacrylic acid copolymer, a dimethicone, a nacreous agent and a cationic polymer, and uses thereof.
HN2003000115A (es) Formulacion farmaceutica que comprende melatonina
SE0001916D0 (sv) Novel formulation
DE60111503D1 (de) Pharmazeutische zusammensetzungen enthaltend terbinafin
NZ528544A (en) Formulations comprising entrapped active ingredients and uses thereof
ATE334658T1 (de) Arzneimittel zur verabreichung an schleimhäute
IT1318578B1 (it) Articolatore, particolarmente per le applicazioni in odontoiatria eodontotecnica.
AU8524801A (en) Polymeric composition

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties